Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids

Journal of Lipid Research

Volumn 53, Issue 7, 2012, Pages 1336-1347

  Zou, Hechang ^a   Yuan, Chong ^a   Dong, Liang ^a   Sidhu, Ranjinder S ^a   Hong, Yu H ^a   Kuklev, Dmitry V ^a   Smith, William L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aspirin; Celecoxib; Cyclooxygenase; Fatty acid; Half of site; Ibuprofen; Naproxen; Oleic acid; Palmitic acid; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; DIMER; FATTY ACID DERIVATIVE; HEME; HETERODIMER; HUMAN PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE 1; HUMAN PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE 2; IBUPROFEN; MONOMER; NONSUBSTRATE FATTY ACID; OLEIC ACID; PALMITIC ACID; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; STEARIC ACID; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME STRUCTURE; FATTY ACID METABOLISM; HUMAN; OXYGENATION; PRIORITY JOURNAL; REGULATORY MECHANISM;

ALLOSTERIC REGULATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; FATTY ACIDS; HUMANS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862305043     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M026856     Document Type: Article

References (57)

1. Smith, W. L., D. L. DeWitt, and R. M. Garavito. 2000. Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 69: 145-182.
2. Schneider, C., D. A. Pratt, N. A. Porter, and A. R. Brash. 2007. Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Chem. Biol. 14: 473-488.
3. Rouzer, C. A., and L. J. Marnett. 2009. Cyclooxygenases: structural and functional insights. J. Lipid Res. 50 (Suppl.): 29-34.
4. Tsai, A. L., and R. Kulmacz. 2010. Prostaglandin H synthase: resolved and unresolved mechanistic issues. Arch. Biochem. Biophys. 493: 103-124.
5. Smith, W. L., Y. Urade, and P. Jakobsson. 2011. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev. 111: 5821-5865.
6. Liu, W., D. Cao, S. F. Oh, C. N. Serhan, and R. J. Kulmacz. 2006. Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 20: 1097-1108.
7. Ohki, S., N. Ogino, S. Yamamoto, and O. Hayaishi. 1979. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 254: 829-836.
8. Liu, J., S. A. Seibold, C. J. Rieke, I. Song, R. I. Cukier, and W. L. Smith. 2007. Prostaglandin endoperoxide H synthases: peroxidase hydroperoxide specificity and cyclooxygenase activation. J. Biol. Chem. 282: 18233-18244.
9. Walker, M. C., R. Kurumbail, J. Kiefer, K. Moreland, C. Koboldt, P. Isakson, K. Seibert, and J. Gierse. 2001. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 357: 709-718.
10. Blobaum, A. L., and L. Marnett. 2007. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 50: 1425-1441.
11. Gierse, J. K., Y. Zhang, W. F. Hood, M. C. Walker, J. S. Trigg, T. J. Maziasz, C. M. Koboldt, J. L. Muhammad, B. S. Zweifel, J. L. Masferrer, et al. 2005. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J. Pharmacol. Exp. Ther. 312: 1206-1212.
12. Burian, M., and G. Geisslinger. 2005. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol. Ther. 107: 139-154.
13. Brune, K., and D. E. Furst. 2007. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology. 46: 911-919.
14. Marnett, L. J., and R. N. DuBois. 2002. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 42: 55-80.
15. Eisinger, A. L., S. M. Prescott, D. A. Jones, and D. M. Stafforini. 2007. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 82: 147-154.
16. Antithrombotic Trialists' Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324: 71-86.
17. Capone, M. L., S. Tacconelli, M. G. Sciulli, M. Grana, E. Ricciotti, P. Minuz, P. Di Gregorio, G. Merciaro, C. Patrono, and P. Patrignani. 2004. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 109: 1468-1471.
18. Patrono, C., L. Garcia Rodriguez, R. Landolfi, and C. Baigent. 2005. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353: 2373-2383.
19. Renda, G., S. Tacconelli, M. Capone, D. Sacchetta, F. Santarelli, M. Sciulli, M. Zimarino, M. Grana, E. D'Amelio, M. Zurro, et al. 2006. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin. Pharmacol. Ther. 80: 264-274.
20. Grosser, T., Y. Yu, and G. A. Fitzgerald. 2010. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med. 61: 17-33.
21. Eikelboom, J. W., J. Hirsh, F. A. Spencer, T. P. Baglin, and J. I. Weitz. 2012. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e89S-119.
22. Yuan, C., R. S. Sidhu, D. V. Kuklev, Y. Kado, M. Wada, I. Song, and W. L. Smith. 2009. Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers. J. Biol. Chem. 284: 10046-10055.
23. Sharma, N. P., L. Dong, C. Yuan, K. R. Noon, and W. L. Smith. 2010. Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. Mol. Pharmacol. 77: 979-986.
24. Dong, L., A. J. Vecchio, N. P. Sharma, B. J. Jurban, M. G. Malkowski , and W. L. Smith. 2011. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J. Biol. Chem. 286: 19035-19046.
25. Yuan, C., C. J. Rieke, G. Rimon, B. A. Wingerd, and W. L. Smith. 2006. Partnering between monomers of cyclooxygenase-2 homodimers. Proc. Natl. Acad. Sci. USA. 103: 6142-6147.
26. Kulmacz, R. J., and W. E. Lands. 1984. Prostaglandin H synthase. Stoichiometry of heme cofactor. J. Biol. Chem. 259: 6358-6363.
27. Kulmacz, R. J., and W. E. Lands. 1985. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J. Biol. Chem. 260: 12572-12578.
28. Sidhu, R. S., J. Lee, C. Yuan, and W. Smith. 2010. Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry. 49: 7069-7079.
29. Barnett, J., J. Chow, D. Ives, M. Chiou, R. Mackenzie, E. Osen, B. Nguyen, S. Tsing, C. Bach, J. Freire, et al. 1994. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim. Biophys. Acta. 1209: 130-139.
30. Laneuville, O., D. K. Breuer, D. L. Dewitt, T. Hla, C. D. Funk, and W. L. Smith. 1994. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271: 927-934.
31. Laneuville, O., D. K. Breuer, N. Xu, Z. H. Huang, D. A. Gage, J. T. Watson, M. Lagarde, D. L. DeWitt, and W. L. Smith. 1995. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J. Biol. Chem. 270: 19330-19336.
32. Gierse, J. K., S. D. Hauser, D. P. Creely, C. Koboldt, S. H. Rangwala, P. C. Isakson, and K. Seibert. 1995. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305: 479-484.
33. Smith, T., J. Leipprandt, and D. L. DeWitt. 2000. Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2. Arch. Biochem. Biophys. 375: 195-200.
34. Prusakiewicz, J. J., K. Duggan, C. Rouzer, and L. Marnett. 2009. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry. 48: 7353-7355.
35. Rimon, G., R. S. Sidhu, D. A. Lauver, J. Y. Lee, N. P. Sharma, C. Yuan, R. A. Frieler, R. C. Trievel, B. R. Lucchesi, and W. L. Smith. 2010. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl. Acad. Sci. USA. 107: 28-33.
36. Burde, T., and G. Rimon. 2002. On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. Eur. J. Pharmacol. 453: 167-173.
37. Rosenstock, M., A. Danon, M. Rubin, and G. Rimon. 2001. Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs. Eur. J. Pharmacol. 412: 101-108.
38. Chen, Y., Y. Yang, F. Wang, K. Wan, K. Yamane, Y. Zhang, and M. Lei. 2006. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc. Natl. Acad. Sci. USA. 103: 13956-13961.
39. Thuresson, E. D., K. M. Lakkides, C. J. Rieke, Y. Sun, B. A. Wingerd, R. Micielli, A. M. Mulichak, M. G. Malkowski, R. M. Garavito, and W. L. Smith. 2001. Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J. Biol. Chem. 276: 10347-10357.
40. Duncan, T., Y. Osawa, R. K. Kutty, G. Kutty, and B. Wiggert. 1999. Heme-binding by Drosophila retinoid- and fatty acid-binding glycoprotein (RFABG), a member of the proapolipophorin gene family. J. Lipid Res. 40: 1222-1228.
41. Huber, W. J., and W. Backes. 2008. Quantitation of heme oxygenase 1: heme titration increases yield of purified protein. Anal. Biochem. 373: 167-169.
42. Titus, B. G., R. Kulmacz, and W. Lands. 1982. Selective destruction and removal of heme from prostaglandin H synthase. Arch. Biochem. Biophys. 214: 824-828.
43. Percival, M. D., M. Ouellet, C. J. Vincent, J. A. Yergey, B. P. Kennedy , and G. P. O'Neill. 1994. Purification and characterization of recombinant human cyclooxygenase-2. Arch. Biochem. Biophys. 315: 111-118.
44. Sprecher, H., M. VanRollins, F. Sun, A. Wyche, and P. Needleman. 1982. Dihomo-prostaglandins and -thromboxane. A prostaglandin family from adrenic acid that may be preferentially synthesized in the kidney. J. Biol. Chem. 257: 3912-3918.
45. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R-L. Moussignac. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037.
46. Bazan, N. G., J. M. Calandria, and C. N. Serhan. 2010. Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J. Lipid Res. 51: 2018-2031.
47. Rouzer, C. A., and L. J. Marnett. 2008. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J. Biol. Chem. 283: 8065-8069.
48. Chen, Y. N., and L. J. Marnett. 1989. Heme prosthetic group required for acetylation of prostaglandin H synthase by aspirin. FASEB J. 3: 2294-2297.
49. Gierse, J. K., C. Koboldt, M. Walker, K. Seibert, and P. Isakson. 1999. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 339: 607-614.
50. Duggan, K. C., M. J. Walters, J. Musee, J. M. Harp, J. R. Kiefer, J. A. Oates, and L. J. Marnett. 2010. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J. Biol. Chem. 285: 34950-34959.
51. Simmons, D. L., R. M. Botting, and T. Hla. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56: 387-437.
52. Smith, W. L. 2008. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem. Sci. 33: 27-37.
53. Rome, L. H., and W. E. Lands. 1975. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by antiinflammatory drugs. Proc. Natl. Acad. Sci. USA. 72: 4863-4865.
54. Duggan, K. C., D. Hermanson, J. Musee, J. Prusakiewicz, J. Scheib, B. Carter, S. Banerjee, J. Oates, and L. Marnett. 2011. (R)-profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat. Chem. Biol. 7: 803-809.
55. Wilner, K. D., M. Rushing, C. Walden, R. Adler, J. Eskra, R. Noveck , and R. Vargas. 2002. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J. Clin. Pharmacol. 42: 1027-1030.
56. Solomon, S. D., J. Wittes, P. V. Finn, R. Fowler, J. Viner, M. M. Bertagnolli, N. Arber, B. Levin, C. L. Meinert, B. Martin, et al. for the Cross Trial Safety Assessment. 2008. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 117: 2104-2113.
57. Gladding, P. A., M. Webster, H. Farrell, I. Zeng, R. Park, and N. Ruijne. 2008. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am. J. Cardiol. 101: 1060-1063.